LIFE SAVING DRUGS PROGRAM EXPERT PANEL

13th MEETING: 14 October 2022

**AGENDA**

1. **Standing business**
   1. Welcome, apologies and potential or actual Conflicts of Interest
   2. Update on actions from previous meetings
   3. Correspondence
   4. Report from the Secretariat
2. **Reviews of existing LSDP medicines**
   1. Review of Elosulfase alfa (Vimizim®)
3. **Applications for new LSDP medicines**
   1. Sebelipase alfa (Kanuma®) – for the treatment of infantile onset lysosomal acid lipase deficiency (L-LAD)
4. **Other business**